Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
CONTEXT: Patients with type 2 diabetes mellitus (T2DM) have clinically relevant disturbances in the effects of the hormone glucose-dependent insulinotropic polypeptide (GIP). OBJECTIVE: We aimed to evaluate the importance of the prevailing plasma glucose levels for the effect of GIP on responses of glucagon and insulin and glucose disposal in patients with T2DM. DESIGN AND SETTING: We performed a single center, placebo-controlled, cross-over, experimental study. PATIENTS: We studied twelve patients with T2DM (age: 62 ± 1 years [mean ± SEM], body mass index: 29 ± 1 kg/m(2); glycosylated hemoglobin A1c: 6.5 ± 0.1% [48 ± 2 mmol/mol]). INTERVENTION: We infused physiological amounts of GIP (2 pmol × kg(-1) × min(-1)) or saline. MAIN OUTCOME MEASURES: We measured plasma concentrations of glucagon, glucose, insulin, C-peptide, intact GIP, and amounts of glucose needed to maintain glucose clamps. RESULTS: During fasting glycemia (plasma glucose ∼8 mmol/L), GIP elicited significant increments in both insulin and glucagon levels, resulting in neutral effects on plasma glucose. During insulin-induced hypoglycemia (plasma glucose ∼3 mmol/L), GIP elicited a minor early-phase insulin response and increased glucagon levels during the initial 30 minutes, resulting in less glucose needed to be infused to maintain the clamp (29 ± 8 vs 49 ± 12 mg × kg(-1), P < .03). During hyperglycemia (1.5 × fasting plasma glucose ∼12 mmol/L), GIP augmented insulin secretion throughout the clamp, with slightly less glucagon suppression compared with saline, resulting in more glucose needed to maintain the clamp during GIP infusions (265 ± 21 vs 213 ± 13 mg × kg(-1), P < .001). CONCLUSIONS: In patients with T2DM, GIP counteracts insulin-induced hypoglycemia, most likely through a predominant glucagonotropic effect. In contrast, during hyperglycemia, GIP increases glucose disposal through a predominant effect on insulin release.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationT., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Insulin resistance as the core defect in type 2 diabetes mellitus
Goldstein, B. J. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02553-5 · Cited by 432 · cited 1×
“The insulin dose and the insulin resistance typical for patients with T2DM (26) are probably also important for the observed net effect on plasma glucose (and need for glucose administration).”
BackgroundVilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Self-citationHøjberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Self-citationDunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Shah, P., Vella, A., Basu, A., Basu, R., Schwenk, W. F., & Rizza, R. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6993 · Cited by 368
Glucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Self-citationMeier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Self-citationMeier, J. J., & Nauck, M. A. (2010) · Diabetes · doi:10.2337/db09-1899 · Cited by 215
Research works printed but not linked: 27
- Jones, 1987, The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion, Diabetologia, 30, 707, 10.1007/BF00296993 · DOI
- Meier, 2001, Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes, Diabetes, 50, 2497, 10.2337/diabetes.50.11.2497 · DOI · Paper page
- Krarup, 1987, Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus, Metab Clin Exp, 36, 677, 10.1016/0026-0495(87)90153-3 · DOI
- Elahi, 1994, The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7–37) in normal and diabetic subjects, Regul Pept, 51, 63, 10.1016/0167-0115(94)90136-8 · DOI · Paper page
- Meier, 2004, Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects, Diabetes 53, 33, S220, 10.2337/diabetes.53.suppl_3.S220 · DOI
- Holst, 2011, Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes, Diabetes Care, 34, S251, 10.2337/dc11-s227 · DOI · Paper page
- Knop, 2007, Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus, Diabetologia, 50, 797, 10.1007/s00125-006-0566-z · DOI · Paper page
- Lund, 2011, The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes, Am J Physiol Endocrinol Metab, 300, E1038, 10.1152/ajpendo.00665.2010 · DOI · Paper page
- Chia, 2009, Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes, Diabetes, 58, 1342, 10.2337/db08-0958 · DOI · Paper page
- Carr, 2008, Incretin and islet hormonal responses to fat and protein ingestion in healthy men, Am J Physiol Endocrinol Metab, 295, E779, 10.1152/ajpendo.90233.2008 · DOI · Paper page
- Christensen, 2011, The α-cell as target for type 2 diabetes therapy, Rev Diabet Stud, 8, 369, 10.1900/RDS.2011.8.369 · DOI · Paper page
- Aaboe, 2010, Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus, Diabetes Obes Metab, 12, 323, 10.1111/j.1463-1326.2009.01167.x · DOI
- Christensen, 2010, Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes, Regul Pept, 163, 96, 10.1016/j.regpep.2010.05.004 · DOI
- Van Cauter, 1992, Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance, Diabetes, 41, 368, 10.2337/diabetes.41.3.368 · DOI
- Kjems, 2000, Validation of methods for measurement of insulin secretion in humans in vivo, Diabetes, 49, 580, 10.2337/diabetes.49.4.580 · DOI
- Kjems, 2001, Quantification of β-cell function during IVGTT in Type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods, Diabetologia, 44, 1339, 10.1007/s001250100639 · DOI
- Glantz, 2005, Primer of Biostatistics
- Ahrén, 2008, Clinical measures of islet function: usefulness to characterize defects in diabetes, Curr Diabetes Rev, 4, 129, 10.2174/157339908784220714 · DOI
- Gromada, 2007, α-cells of the endocrine pancreas: 35 years of research but the enigma remains, Endocr Rev, 28, 84, 10.1210/er.2006-0007 · DOI · Paper page
- Ipp, 2000, Impaired glucose tolerance: the irrepressible α-cell?, Diabetes Care, 23, 569, 10.2337/diacare.23.5.569 · DOI
- Ahrén, 2009, β- and α-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal caucasian women, Diabetes, 58, 726, 10.2337/db08-1158 · DOI
- Aaboe, 2009, KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes, J Clin Endocrinol Metab, 94, 603, 10.1210/jc.2008-1731 · DOI · Paper page
- Wice, 2012, Xenin-25 amplifies GIP-mediated insulin secretion in humans with normal and impaired glucose tolerance but not type 2 diabetes, Diabetes, 61, 1793, 10.2337/db11-1451 · DOI
- Nauck, 2011, Blocking GLP-1 action with exendin [9–39] to determine the contribution of GLP-1 to the insulinotropic effects of the DPP-4 inhibitor vildagliptin, Diabetologia, 54, S108
- Seck, 2010, Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study, Int J Clin Pract, 64, 562, 10.1111/j.1742-1241.2010.02353.x · DOI · Paper page
- Ahrén, 2009, Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes, J Clin Endocrinol Metab, 94, 1236, 10.1210/jc.2008-2152 · DOI · Paper page
- Schweizer, 2013, Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin, Vasc Health Risk Manag, 9, 57, 10.2147/VHRM.S40972 · DOI
Cited by
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“Similar results are reported in patients with type 2 diabetes, in which GIP counteracts insulin-induced hypoglycemia (104) and increases postprandial glucagon levels (100, 397), implying that it is a bifunctional regulator of islet hormone secretion (reviewed in Ref.”
ResultNauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
Deacon, C. F. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0399-8 · Cited by 398
Metadata
- Authors
- Christensen, M. B., Calanna, S., Holst, J. J., Vilsbøll, T., & Knop, F. K.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-03-01
- Volume
- 99
- Issue
- 3
- Pages
- E418-E426
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2149121623
- Cited by
- 99
- References
- 11
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes. https://app.cochat.ai/papers/10.1210/jc.2013-3644
- The paper
- Christensen, M. B., Calanna, S., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2014). Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2013-3644
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.